Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MONT-SAINT-GUIBERT, Belgium, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell...
-
MONT-SAINT-GUIBERT, Belgium, Nov. 17, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of...
-
First ever morphologic complete response (MLFS1) with gene-engineered T cells without prior pre-conditioning chemotherapy for a patient with relapsed refractory acute myeloid leukemia (AML). ...
-
MONT-SAINT-GUIBERT, Belgium, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell...
-
Celyad’s management will host a conference call at 2pm CEST / 8am EDT today Strong progress in THINK trial with first signals of clinical activity in solid tumorsNon-exclusive license agreement...
-
Ongoing clinical trial development boosts Celyad’s confidence in the future of its oncology assetsCelyad to receive an increased share of future revenues in exchange for $25M worth of cash and Celyad...
-
SHRINK study to evaluate the synergetic effect of the concurrent administration of CYAD-01 (CAR-T NKG2D) with standard chemotherapy in patients suffering from metastatic colorectal cancer ...
-
Review of NKR-2 pre-clinical work published in Future Oncology In vitro efficacy on various cancer models In vivo evidence of efficacy in a human pancreatic model MONT-SAINT-GUIBERT, Belgium, June ...
-
Two metastatic colorectal cancer patients reported as Stable Disease at 3-month follow-upNo toxicity signals reported up to now MONT-SAINT-GUIBERT, Belgium, June 19, 2017 (GLOBE NEWSWIRE) -- ...
-
MONT-SAINT-GUIBERT, Belgium, May 30, 2017 (GLOBE NEWSWIRE) -- Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of engineered cell therapies,...